Literature DB >> 26517773

Early versus late Gamma Knife radiosurgery following transsphenoidal resection for nonfunctioning pituitary macroadenomas: a matched cohort study.

I Jonathan Pomeraniec1, Robert F Dallapiazza1, Zhiyuan Xu1, John A Jane1, Jason P Sheehan1.   

Abstract

OBJECT Gamma Knife radiosurgery (GKRS) is frequently employed to treat residual or recurrent nonfunctioning pituitary macroadenomas. There is no consensus as to whether GKRS should be used early after surgery or if radiosurgery should be withheld until there is evidence of radiographic progression of tumor. METHODS This is a retrospective review of patients with nonfunctioning pituitary macroadenomas who underwent transsphenoidal surgery followed by GKRS between 1996 and 2013 at the University of Virginia Health System. Patients were stratified based on the interval between resection and radiosurgery. Operative results and imaging and clinical outcomes were compared across groups following early (≤ 6 months) or late (> 6 months) radiosurgery. RESULTS Sixty-four patients met the study criteria and were grouped based on early (n = 32) or late (n = 32) GKRS following transsphenoidal resection. There was a greater risk of tumor progression after GKRS in the late radiosurgical group (p = 0.027) over a median radiographic follow-up period of 68.5 months. Furthermore, there was a significantly higher occurrence of post-GKRS endocrinopathy in the late radiosurgical cohort (p = 0.041). Seventeen percent of patients without endocrinopathy in the early cohort developed new endocrinopathies during the follow-up period versus 64% in the late cohort (p = 0.036). This difference was primarily due to a significantly higher rate of tumor growth during the observation period of the late treatment cohort (p = 0.014). Of these patients with completely new endocrinopathies, radiation-associated pituitary insufficiency developed in 1 of 2 patients in the early group and in 3 of 7 (42.9%) patients in the late group. CONCLUSIONS Early treatment with GKRS appears to decrease the rate of radiographic and symptomatic progression of subtotally resected nonfunctioning pituitary macroadenomas compared with late GKRS treatment after a period of expectant management. Delaying radiosurgery may place the patient at increased risk for adenoma progression and endocrinopathy.

Entities:  

Keywords:  GKRS = Gamma Knife radiosurgery; Gamma Knife; IGF-1 = insulin-like growth factor-I; macroadenoma; nonfunctioning; pituitary surgery; radiosurgery; stereotactic radiosurgery; transsphenoidal resection

Mesh:

Year:  2015        PMID: 26517773     DOI: 10.3171/2015.5.JNS15581

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  11 in total

Review 1.  Target delineation and optimal radiosurgical dose for pituitary tumors.

Authors:  Giuseppe Minniti; Mattia Falchetto Osti; Maximillian Niyazi
Journal:  Radiat Oncol       Date:  2016-10-11       Impact factor: 3.481

2.  Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery.

Authors:  Mohana Rao Patibandla; Zhiyuan Xu; Jason P Sheehan
Journal:  J Neurooncol       Date:  2018-02-07       Impact factor: 4.130

3.  Long-term hormonal and imaging outcomes of adjunctive gamma knife radiosurgery in non-functioning pituitary adenomas: a single center experience.

Authors:  Aasim N Maldar; Sanjeev Pattankar; Basant K Misra; Phulrenu H Chauhan; Milind Sankhe; Ketan Desai; N F Shah
Journal:  J Neurooncol       Date:  2022-05-20       Impact factor: 4.130

4.  Debulking surgery of pituitary adenoma as a strategy to facilitate definitive stereotactic radiosurgery.

Authors:  Neil Forster; Ronald Warnick; Vinita Takiar; Luke Pater; John Breneman
Journal:  J Neurooncol       Date:  2018-02-15       Impact factor: 4.130

5.  Frequency, pattern, and outcome of recurrences after gamma knife radiosurgery for pituitary adenomas.

Authors:  Marco Losa; Giorgio Spatola; Luigi Albano; Alessandra Gandolfi; Antonella Del Vecchio; Angelo Bolognesi; Pietro Mortini
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

6.  Early versus late Gamma Knife radiosurgery following transsphenoidal surgery for nonfunctioning pituitary macroadenomas: a multicenter matched-cohort study.

Authors:  I Jonathan Pomeraniec; Hideyuki Kano; Zhiyuan Xu; Brandon Nguyen; Zaid A Siddiqui; Danilo Silva; Mayur Sharma; Hesham Radwan; Jonathan A Cohen; Robert F Dallapiazza; Christian Iorio-Morin; Amparo Wolf; John A Jane; Inga S Grills; David Mathieu; Douglas Kondziolka; Cheng-Chia Lee; Chih-Chun Wu; Christopher P Cifarelli; Tomas Chytka; Gene H Barnett; L Dade Lunsford; Jason P Sheehan
Journal:  J Neurosurg       Date:  2017-10-27       Impact factor: 5.115

Review 7.  Proton and Heavy Particle Intracranial Radiosurgery.

Authors:  Eric J Lehrer; Arpan V Prabhu; Kunal K Sindhu; Stanislav Lazarev; Henry Ruiz-Garcia; Jennifer L Peterson; Chris Beltran; Keith Furutani; David Schlesinger; Jason P Sheehan; Daniel M Trifiletti
Journal:  Biomedicines       Date:  2021-01-03

8.  Correlation between the Expression of Interleukin-6, STAT3, E-Cadherin and N-Cadherin Protein and Invasiveness in Nonfunctional Pituitary Adenomas.

Authors:  Xiaoxu Shen; Qi Liu; Jian Xu; Yang Wang
Journal:  J Neurol Surg B Skull Base       Date:  2019-12-05

9.  Deferred Radiotherapy After Debulking of Non-functioning Pituitary Macroadenomas: Clinical Outcomes.

Authors:  Sarah E Nicholas; Roberto Salvatori; Alfredo Quinones-Hinojosa; Kristin Redmond; Gary Gallia; Michael Lim; Daniele Rigamonti; Henry Brem; Lawrence Kleinberg
Journal:  Front Oncol       Date:  2019-01-10       Impact factor: 6.244

10.  Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion.

Authors:  Rupesh Kotecha; Arjun Sahgal; Muni Rubens; Antonio De Salles; Laura Fariselli; Bruce E Pollock; Marc Levivier; Lijun Ma; Ian Paddick; Jean Regis; Jason Sheehan; Shoji Yomo; John H Suh
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.